Zacks.com on MSN18h
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...
The American Journal of Managed Care15h
Rise of Innovative Therapies for Breast Cancer Treatment
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and ...
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
Medscape1mon
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...
SurvivorNet1mon
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor as treatment for people with HR+/HER2- stage II and III early breast ...
Monthly Prescribing Reference1mon
Kisqali Approved for HR-Positive, HER2-Negative Early Breast Cancer
Treatment with ribociclib plus endocrine therapy significantly reduced the risk of disease recurrence by 25.1% compared with endocrine therapy alone. The primary endpoint was invasive disease-free ...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...
Pharmabiz3d
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...
precisionmedicineonline3d
CHMP Recommends Approving Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer
The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.
casereports.bmj3mon
Ribociclib-associated organising pneumonia
A 63-year-old woman with grade 2 infiltrating left breast carcinoma who was started on ribociclib complained of exertional dyspnoea along with dry cough. There were bilateral interscapular crackles ...
MedPage Today14d
Nagi El Saghir, MD, on What to Learn From the Final Results of the RIGHT Choice Trial
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recent clinical trial data suggested a new first-line ...
Federal Register7d
Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; KISQALI (ribociclib)
This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...